Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Doribax; Belgium: Doribax; Bulgaria: Doribax; Cyprus: Doribax; Czech Republic: Doribax; Denmark: Doribax; Estonia: Doribax; Finland: Doribax; France: Doribax; Germany: Doribax; Greece: Doribax; Hungary: Doribax; Ireland: Doribax; Italy: Doribax; Latvia: Doribax; Lithuania: Doribax; Malta: Doribax; Netherlands: Doribax; Poland: Doribax; Portugal: Doribax; Romania: Doribax; Slovakia: Doribax; Slovenia: Doribax; Spain: Doribax; Sweden: Doribax; UK: Doribax.

North America

Canada: Doribax; USA: Doribax.

Latin America

Argentina: Doribax.


Japan: Finibax.

Drug combinations


Doripenem: C~15~H~24~N~4~O~6~S~2~. Mw: 420.50. (1) 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[[(aminosulfonyl)amino]methyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-; (2)(+)-(4R,5S,6S)-6-[(1R)-1-Hydroxyethyl]-4-methyl-7-oxo-3-[[(3S,5S)-5-[(sulfamoylamino)methyl]-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid. CAS-148016-81-3 (2005).

Pharmacologic Category

Antibacterials; Miscellaneous β-Lactams; Carbapenems. (ATC-Code: J01DH04).

Mechanism of action

Synthetic carbapenem β-lactam antibiotic. Doripenem exerts its bactericidal activity by inhibiting cell wall synthesis in susceptible organisms. Has a broad spectrum of activity and is active in vitro against many Gram-negative and Gram-positive aerobic and anaerobic bacteria.

Therapeutic use

Used for the treatment of complicated intra-abdominal infections caused by susceptible Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. caccae, B. thetaiotaomicron, B. uniformis, B. vulgatus, Streptococcus intermedius, Streptococcus constellatus, or Peptostreptococcus micros. Also used for the treatment of complicated urinary tract infections (including pyelonephritis) caused by susceptible E. coli (including cases with concurrent bacteremia) or susceptible K. pneumoniae, Proteus mirabilis, Ps. aeruginosa, or Acinetobacter baumannii.

Pregnancy and lactiation implications

Adverse events not observed in animal studies. No adequate, well-controlled studies completed in pregnant women. It is not known if doripenem is excreted into breast milk. Use with caution when administered during lactation.

Unlabeled use

Treatment of nosocomial pneumonia.


Known serious hypersensitivity to doripenem or other carbapenems (e.g. imipenem, ertapenem, meropenem). Anaphylactic reactions to β-lactam antibiotics.

Warnings and precautions

Serious hypersensitivity reactions, including anaphylaxis, and skin reactions reported in patients receiving β-lactams. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. Levels of valproic acid may be decreased (potential for breakthrough seizures). Administer via I.V. infusion only.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart